Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session By Benzinga

©Reuters. Why Are Netcapital Shares Trading Over 33% Lower? Here are 49 stocks moving into Wednesday’s midday session

gasoline gas winner

Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics posted a Q3 loss of $0.18 per share last month.
Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares rose 140% to $0.6041 after the company signed a definitive merger agreement with GRI Bio.
Immix Biopharma, Inc. (NASDAQ: IMMX) surged 46% to $2.1695 after the company announced it had launched next-generation BCMA-targeted CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR in the therapeutic dose from the first 20 patients in an ongoing Phase 1b clinical trial in relapsed/refractory multiple myeloma.
Senti Biosciences, Inc. (NASDAQ:SNTI) rose 45% to $2.09 after falling more than 21% on Tuesday.
Avidity Biosciences, Inc. (NASDAQ: RNA) shares rose 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA study, which was the first-ever successful targeted issuance of RNA in muscles demonstrated.
BIMI International Medical, Inc. (NASDAQ: BIMI) is up 28.1% to $2.6649. BIMI announced the completion of a material definitive agreement to acquire Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co.,Ltd.
Wave Life Sciences Ltd. (NASDAQ:WVE) is up 21.1% to $5.80. SVB Leerink held WAVE Life Sciences with a market perform and raised the price target to $7 from $2.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares rose 21.4% to $31.38 after the company shared results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi’s decision ( EPA:) had announced that it was advancing KT-474 into Phase 2 clinical trials.
Aspen Group, Inc. (NASDAQ:ASPU) gained 17.4% to $0.41 after reporting strong quarterly sales.
REV Group, Inc. (NYSE: REVG) rose 17.2% to $15.57 as the company reported fourth-quarter fiscal 22 revenue grew 5.7% year over year to $623.6 million, beating the consensus of $595 million surpassed $.
Nuvve Holding Corp. (NASDAQ:NVVE) is up 16.9% to $0.7477.
Meiwu Technology Company Limited (NASDAQ:WNW) rose 16.3% to $2.14.
United Insurance Holdings Corp. (NASDAQ:UIHC) is up 16.2% to $0.5578.
Dyne Therapeutics, Inc. (NYSE:DYN) is up 14.7% to $14.00.
Sio Gene Therapies Inc. (NASDAQ:SIOX) is up 14.7% to $0.3537.
Otonomy, Inc. (NASDAQ:OTIC) is up 14.4% at $0.1399.
Harmonic Inc. (NASDAQ:HLIT) was up 12.9% to $14.86
Happiness Development Group Limited (NASDAQ:HAPP) is up 12.9% to $3.9973 after rising over 10% on Tuesday.
Carvana Co. (NYSE:CVNA) was up 12.8% to $5.45.
Treasure Holdings, Inc. (NASDAQ:SFR) rose 12.4% to $1.90.
Harrow Health, Inc. (NASDAQ:HROW) was up 11.9% to $12.43. Harrow Health entered into a binding agreement to acquire exclusive US commercial rights to five FDA-cleared ophthalmic products from Novartis.
Mullen Automotive, Inc. (NASDAQ: MULN) is up 10% to $0.2354. Mullen Automotive has partnered with Loop Global to provide EV charging solutions, including a public DC fast charging network and residential offerings.
Qualtek Services Inc. (NASDAQ:QTEK) is up 9.3% to $0.5463.
Cytokinetics, Incorporated (NASDAQ:CYTK) was up 7.6% to $41.27. The FDA’s Advisory Committee on Cardiovascular and Renal Drugs voted 8 to 3 against approval of Cytokinetics’ heart failure drug, Omecamtiv Mecarbil.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) was up 6.3% to $2.02. According to Processa Pharmaceuticals, PCS12852 successfully improves clinical symptoms associated with gastroparesis in Phase 2A studies.

loser

DriveShack Inc. (NYSE:DS) fell 55.3% to $0.2126. The company announced its intention to voluntarily delist from the NYSE and deregister its common stock.
ZyVersa Therapeutics Inc (NASDAQ:ZVSA) fell 36.5% to $4.76.
Netcapital Inc. (NASDAQ: NCPL) shares fell 33.3% to $1.47 after the company announced pricing for a public offering.
OpGen, Inc. (NASDAQ:OPGN) fell 29.8% to $0.1621. OpGen shares rose about 85% on Tuesday after the company announced top-line data from its Unyvero urinary tract infection (UTI) clinical trial.
Puhui Wealth Investment Management Co., Ltd. (NASDAQ:PHCF) fell 25.7% to $2.95.
Kaspien Holdings Inc. (NASDAQ: KSPN) fell 24.2% to $0.7490 after the company reported a larger loss in the third quarter.
Against Systems Inc. (NASDAQ:VS) is down 23.1% at $0.5998.
SeqLL Inc. (NASDAQ:SQL) fell 21.7% to $0.3789.
Vincerx Pharma, Inc. (NASDAQ:VINC) is down 21.7% at $0.83.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) fell 20.9% to $6.52.
Getaround, Inc. (NYSE: GETR) fell 20.4% to $1.09.
Bit Brother Limited (NASDAQ: BTB) fell 20% to $0.4238 after the company announced a 1:15 reverse stock split.
Oriental Culture Holding LTD (NASDAQ:OCG) is down 18.8% at $0.71.
Yumanity Therapeutics, Inc. (NASDAQ:YMTX) fell 16.8% to $1.6886. Yumanity Therapeutics recently announced a special dividend in connection with its proposed sale of assets to Janssen and its merger with Kineta.
Baudax Bio, Inc. (NASDAQ: BXRX) fell 16.6% to $2.5925.
Summit Therapeutics Inc. (NASDAQ:SMMT) fell 16.4% to $3.2691.
Bright Health Group, Inc. (NYSE:BHG) fell 16% to $0.6137. Goldman Sachs (NYSE:) downgraded Bright Health to Sell from Neutral on Tuesday.
Arquit Quantum Inc. (NASDAQ: ARQQ) fell 14.7% to $5.33 after the company reported FY22 results and requested a mixed shelf of up to $100 million.
Charter Communication (NASDAQ:), Inc. (NASDAQ: CHTR) fell 13.3% to $340.65 after announcing an increase in capital spending for 2023 at its analyst day on Tuesday.
Rubicon Technology, Inc. (NASDAQ:RBCN) shares fell 13.1% to $1.5814. Rubicon Technology announced a voluntary delisting from Nasdaq.
Nexalin Technology, Inc. (NASDAQ:NXL) fell 11.1% to $1.7250.
Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) fell 11% to $12.32.
LAVA Therapeutics NV (NASDAQ:LVTX) fell 9.4% to $4.20. LAVA Therapeutics announced updated data from the Phase 1/2a clinical trial of LAVA-051 at the 64th Annual Meeting and Exposition of the American Society of Hematology.
Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 7.1% to $0.1327 after gaining around 53% on Tuesday. Panbela received the EMA orphan status statement for ivospemin in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.